Litcius/Paper detail

OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial

B. Besse, Giuseppe Lo Russo, H. Léna, E. Nadal, S. Cousin, Dariusz M. Kowalski, Michael E. Johnson, Silvia Novello, H. Bischoff, N. Girard, J-L. Pujol, L. Paz-Ares, Semra Yörük, Anais Tellier, Byoung Chul Cho

2024Journal of Thoracic Oncology24 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDocetaxelOncologyInternal medicineChemotherapyCancer Treatment and PharmacologyHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial | Litcius